Patient specific treatment sequencing in ER plus advanced breast cancer

被引：0
|
作者：
Johnston, Stephen [1 ,2 ,3 ]
机构：
[1] Royal Marsden NHS Fdn Trust, Breast Canc Med, London, England
[2] Royal Marsden NHS Fdn Trust, London, England
[3] Inst Canc Res, London, England
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2020年 / 180卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：590 / 590
页数：1
相关论文
共 50 条
  • [41] Capivasertib plus fulvestrant in advanced breast cancer
    Lorenz, Judith
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2023, 83 (09) : 1057 - 1057
  • [42] Paclitaxel plus epirubicin in advanced breast cancer
    Conte, PF
    Gennari, A
    Salvadori, B
    Pazzagli, I
    Bengala, C
    ONCOLOGY-NEW YORK, 1998, 12 (01): : 40 - 44
  • [43] Ribociclib plus Fulvestrant in Advanced Breast Cancer
    Hindie, Elif
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (23):
  • [44] Doxorubicin plus paclitaxel in advanced breast cancer
    Dombernowsky, P
    Boesgaard, M
    Andersen, E
    Jensen, PV
    SEMINARS IN ONCOLOGY, 1997, 24 (05) : 15 - 18
  • [45] Tumor Sequencing and Patient-Derived Xenografts in the Neoadjuvant Treatment of Breast Cancer
    Goetz, Matthew P.
    Kalari, Krishna R.
    Suman, Vera J.
    Moyer, Ann M.
    Yu, Jia
    Visscher, Daniel W.
    Dockter, Travis J.
    Vedell, Peter T.
    Sinnwell, Jason P.
    Tang, Xiaojia
    Thompson, Kevin J.
    McLaughlin, Sarah A.
    Moreno-Aspitia, Alvaro
    Copland, John A.
    Northfelt, Donald W.
    Gray, Richard J.
    Hunt, Katie
    Conners, Amy
    Weinshilboum, Richard
    Wang, Liewei
    Boughey, Judy C.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2017, 109 (07):
  • [46] Doxorubicin plus ifosfamide as salvage treatment for patients with advanced breast cancer refractory to epirubicin plus cyclophosphamide
    Polyzos, A
    Kosmas, C
    Tsavaris, N
    Markopoulos, C
    Kalahanis, N
    Papadopoulos, O
    Arnaouti, T
    Sfikakis, PP
    CLINICAL DRUG INVESTIGATION, 2000, 19 (05) : 349 - 355
  • [47] Doxorubicin plus Ifosfamide as Salvage Treatment for Patients with Advanced Breast Cancer Refractory to Epirubicin plus Cyclophosphamide
    Aristidis Polyzos
    C. Kosmas
    N. Tsavaris
    C. Markopoulos
    N. Kalahanis
    O. Papadopoulos
    T. Arnaouti
    P. P. Sfikakis
    Clinical Drug Investigation, 2000, 19 : 349 - 355
  • [48] A role for fulvestrant monotherapy in the first-line treatment of ER plus metastatic breast cancer?
    Mahtani, Reshma L.
    BREAST JOURNAL, 2020, 26 (02): : 109 - 111
  • [49] Multifunctionalized biocatalytic P22 nanoreactor for combinatory treatment of ER plus breast cancer
    Chauhan, Kanchan
    Hernandez-Meza, Juan M.
    Rodriguez-Hernandez, Ana G.
    Juarez-Moreno, Karla
    Sengar, Prakhar
    Vazquez-Duhalt, Rafael
    JOURNAL OF NANOBIOTECHNOLOGY, 2018, 16
  • [50] THE CARE OF THE PATIENT WITH ADVANCED CANCER OF THE BREAST
    CANTRIL, ST
    RADIOLOGY, 1956, 66 (01) : 46 - 54
12345